While safe and effective vaccines are available for Hepatitis A and B, Hepatitis C has largely remained a socioeconomic burden and chronic illness. More than 170 million persons globally suffer from hepatitis C virus (HCV). The good news is that new innovations in treatment options have recently made curing the disease more possible than ever before. Unfortunately, these new drugs may cost tens of thousands of dollars. Unless economic barricades towards providing treatment for all are addressed, the desire of eradicating hepatitis infection worldwide may not be fully realized.